CALQUENCE® (acalabrutinib) Safety Data - Dr Levy, MD

Please see Full Prescribing Information: bit.ly/3Ly3ru0
This video is intended for US healthcare professionals only.
Yair Levy, MD emphasizes the importance of cardiovascular risks in chronic lymphocytic leukemia (CLL) patients and discusses CALQUENCE safety profile, including select cardiovascular safety data.
Topics include the overview and results of ELEVATE-TN, ASCEND and ELEVATE-RR phase 3 trials, including select cardiovascular safety data and discontinuation rates.
Select Safety Information
CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity, including drug-induced liver injury. The most common adverse reactions (≥30%) of any grade in patients with CLL were anemia, neutropenia, thrombocytopenia, headache, upper respiratory tract infection, and diarrhea.